Therefore, although MSI testing has attracted attention as a biomarker for PD-1 blockade32, an assessment of somatic mutation frequency and POLE mutation is instead recommended at least for patients with colorectal or uterine cancer. The gene discussed is POLE; the disease is uterine cancer.